Bristol Myers Squibb reports interim MS data from CAR T study
Bristol Myers Squibb announced Oct. 23 interim safety and efficacy results from a Phase 1 study evaluating an investigational CAR T cell therapy in patients with highly active rela...
Bristol Myers Squibb announced Oct. 23 interim safety and efficacy results from a Phase 1 study evaluating an investigational CAR T cell therapy in patients with highly active rela...
The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China
SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II...
GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars,...
HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibod...
Spanish researchers have developed a humanized monoclonal antibody, hB101.37, that inhibits the BAMBI pseudoreceptor and rebalances T cell immunity, showing therapeutic efficacy an...
A patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.
HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company fo...
SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ded...
Corexa Pharmacy to dispense compounded BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax in accordance with HHS' recently updated Enforcement Discretion PolicyBulk drug substance ac...
PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor respo...
- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.
HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-...
SHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinic...
Interim clinical data of SynKIRâ„¢-310, a CD19-targeted KIR-CAR T therapy, showed no CRS, ICANS, or DLT in the first two dose levels, coupled with robust antitumor activity in pati...
Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy ad...
A receptor-interacting protein kinase 2 scaffolding inhibitor significantly improved clinical remission in moderately to severely active ulcerative colitis, according to results pr...
A receptor-interacting protein kinase 2 scaffolding inhibitor significantly improved clinical remission in moderately to severely active ulcerative colitis, according to results pr...
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Figh...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.